G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival
David Sanford,Courtney D. DiNardo,Guilin Tang,Jorge E. Cortes,Srdan Verstovsek,Elias Jabbour,Farhad Ravandi,Hagop M. Kantarjian,Guillermo Garcia-Manero +8 more
TL;DR: The acquisition of a Jumping translocations appears to be a late event and is associated with myelodysplasia, which was associated with a poor prognosis with apoor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.
Journal ArticleDOI
Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
Rami S. Komrokji,Uwe Platzbecker,Pierre Fenaux,Guillermo Garcia-Manero,Ghulam J. Mufti,Valeria Santini,María Díez-Campelo,Carlo Finelli,Joseph G. Jurcic,Peter L. Greenberg,Mikkael A. Sekeres,Amer M. Zeidan,Amy E. DeZern,Michael R. Savona,Jeevan K. Shetty,Rodrigo Ito,George Zhang,Xianwei Ha,Daniel Sinsimer,Jay Backstrom,Amit Verma +20 more
TL;DR: This paper presents a meta-analyses of the prophylactic and adjuvant properties of six chemotherapy drugs and some of the drugs used in conjunction with each other to treat leukaemia and other types of cancer.
Posted ContentDOI
Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy
Hussein A. Abbas,Dapeng Hao,Katarzyna Tomczak,Praveen Barrodia,Jin Seon Im,Patrick K. Reville,Zoe Alaniz,Wei Wang,Ruiping Wang,Feng Wang,Gheath Alatrash,Koichi Takahashi,Jing Ning,Maomao Ding,Maomao Ding,Jairo T. Mathews,Latasha Little,Jianhua Zhang,Sreyashi Basu,Marina Konopleva,Guillermo Garcia-Manero,Michael R. Green,Padmanee Sharma,James P. Allison,Steven M. Kornblau,Kunal Rai,Linghua Wang,Naval Daver,Andrew Futreal +28 more
TL;DR: The results reveal AML intrinsic characteristics (chromosome 7/7q status and oxidative stressors) and tumor microenvironment to modulate responses to checkpoint blockers and support an adaptable T cell plasticity in response to PD-1 blockade in AML.
Journal ArticleDOI
Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.
John Delmonte,Hagop M. Kantarjian,Guillermo Garcia-Manero,Zeev Estrov,Farhad Ravandi,Srdan Verstovsek,Susan O'Brien,Charles Koller,Stefan Faderl,Deborah A. Thomas,John J. Wright,Jorge E. Cortes +11 more
TL;DR: It is concluded that Z combined with IA induces a high rate of CR in high-risk MDS or AML, but the outcome may not be superior to what is obtained with IA alone.
Journal ArticleDOI
First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).
Elizabeth A. Griffiths,Hagop M. Kantarjian,Gail J. Roboz,Patricia Kropf,Casey O'Connell,Karen W.L. Yee,Guillermo Garcia-Manero,Elias Jabbour,Eric J. Feldman,Katherine Walsh,David A. Rizzieri,Wendy Stock,Scott D. Lunin,Sue Naim,Gavin Choy,Pietro Taverna,Yong Hao,Mohammad Azab,Woonbok Chung,Jean Pierre J. Issa +19 more
TL;DR: The first results of the daily x 10 Q 28 days regimen using 60 mg/m2/d are reported, which results in extended decitabine exposure in patients with r/r AML.